By analyzing the GEO database, we found that BTG2 levels were significantly upregulated in several cancers, including lung cancer (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56757) and prostate cancer (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65965), after knockdown of PRMT5. The gene discussed is PRMT5; the disease is prostate carcinoma.